Targeted therapies with the aim of improving the quality of life of patients treated obligation get information.

About Genentech BioOncologyGenentech is changing the type of cancer by establishing a broad oncology portfolio of innovative, targeted therapies with the aim of improving the quality of life of patients treated obligation. The company is the leading provider of anti-tumor therapeutics in the United States. Genentech is conducting clinical development programs for Rituxan? , Herceptin? , Avastin? and Tarceva? , and markets all four products in the United States, either alone or with Biogen Idec Inc get information . or OSI Pharmaceuticals .

In the year 1993, a study in the journal Nature, Ferrara and his team demonstrated that could be the VEGF antibody directed to suppress angiogenesis and tumor growth in preclinical models, provides compelling evidence that play VEGF play an important role in tumor growth published. Clinical trials with a humanized version of the antibody, Avastin, began in 1997.

Investors and others be advised that a plurality of factor, including some risks, may affect our business and cause actual results to differ materially from those in the forward-looking statements. Risk factors risk factors, without limitation: our failure to to assess just but arise do not medical costs designated benefit, the pricing pressure on to us by managed care agencies and the level of payment exerted we receive under governmental Programmes and from other payers, for future laws of and modifications in governmental regulations, the effects of by Medicare risk adjustments for pay we will obtain to our managed care operations, the losses of our important contracts or from increase the value of Medicare eligible patient is still alive administer we under these contracts, our ability to successfully operation of a health organization of any other known to as an HMO, and Enrolment continuously increase enrollment and effectively manage charges in our HMO. Company is even subject to the risks and uncertainty in the its filings with the Securities and Exchange Commission, including its Annual Report on Form 10 – K for year ended 31 December 2006 its Quarterly Report on Form 10 – quarter ended 30 quarter ended 30 March 2007, its Quarterly Report on Form 10 – Q for the three months the 30th June 2007 Quarterly Reports on Form 10-Q to the quarter ended 30 September 2007.